Migraine prevention drug trial in kids halted early
NCT ID NCT04050293
First seen Nov 21, 2025 · Last updated Jun 23, 2026 · Updated 22 times
Summary
This study tested a drug called SPN-538 to prevent migraines in children aged 6 to 11. The trial was a randomized, double-blind, placebo-controlled study, meaning some children got the drug and some got a placebo. However, the study was terminated early and only enrolled 26 participants, so we cannot draw firm conclusions about its effectiveness or safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEADACHE DISORDERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CNS Healthcare
Memphis, Tennessee, 38119, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SPN-538 (a drug to prevent migraines)
What this could lead to
If it worked, this could offer a new option to reduce migraine frequency in young children.
What could go wrong
The trial was terminated early with very few participants, so results are limited and may not be reliable. It is unclear if SPN-538 is safe or effective for this age group.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.